WallStreetZenWallStreetZen

NASDAQ: CAPR
Capricor Therapeutics Inc Stock Ownership - Who owns Capricor Therapeutics?

Insider buying vs selling

Have Capricor Therapeutics Inc insiders been buying or selling?
Buy
Sell
NameRoleDateSharesPriceValue
Earl M. Collier Jr.Director2024-04-2330,000$1.39
$41.70kBuy
David B. MusketDirector2024-04-2316,156$1.39
$22.46kBuy
Anthony BergmannCHIEF FINANCIAL OFFICER2023-10-232,178$1.39
$3.03kBuy
David B. MusketDirector2023-10-12410$2.75
$1.13kBuy
Earl M. Collier Jr.Director2023-10-1010,000$2.83
$28.30kBuy
David B. MusketDirector2023-10-095,083$2.82
$14.33kBuy
Paul Gisbert AuwaerterDirector2023-10-065,000$2.84
$14.20kBuy
David B. MusketDirector2023-10-042,500$2.90
$7.25kBuy
Frank LitvackDirector2023-08-1420,748$1.39
$28.84kBuy
Frank LitvackDirector2023-08-144,364$6.61
$28.85kSell

1 of 2

CAPR insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when CAPR insiders and whales buy or sell their stock.

CAPR Shareholders

What type of owners hold Capricor Therapeutics Inc stock?
Institutional
Insider
Retail
NameHoldSharesValueType
Fountainhead Capital Partners Ltd17.68%5,551,000$30.03MInsider
Sinai Medical Center Cedars12.90%4,049,959$21.91MInsider
Eduardo Marban10.53%3,307,863$17.90MInsider
John Edward A. St9.88%3,101,574$16.78MInsider
Louis J. Grasmick9.36%2,937,729$15.89MInsider
Peter M. Kash9.30%2,920,446$15.80MInsider
Wexford Capital LP8.30%2,606,778$14.10MInsider
Peter Morgan Kash6.86%2,153,913$11.65MInsider
David M. Tanen6.16%1,934,528$10.47MInsider
Vanguard Group Inc3.71%1,165,404$6.30MInstitution

1 of 3

CAPR vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
CAPR11.23%88.77%Net BuyingNet Buying
CGEN11.98%0.00%
IVA9.33%0.00%
GLSI4.02%95.98%Net BuyingNet Buying
MDWD27.28%0.00%

Capricor Therapeutics Stock Ownership FAQ

Who owns Capricor Therapeutics?

Capricor Therapeutics (NASDAQ: CAPR) is owned by 12.79% institutional shareholders, 101.11% Capricor Therapeutics insiders, and 0.00% retail investors. Fountainhead Capital Partners Ltd is the largest individual Capricor Therapeutics shareholder, owning 5.55M shares representing 17.68% of the company. Fountainhead Capital Partners Ltd's Capricor Therapeutics shares are currently valued at $30.03M.

If you're new to stock investing, here's how to buy Capricor Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.